Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 123Carcinoma, Hepatocellular 72Neoplasms 48Breast Neoplasms 48Small Cell Lung Carcinoma 46Lung Neoplasms 42Triple Negative Breast Neoplasms 40Colorectal Neoplasms 39Melanoma 35Urinary Bladder Neoplasms 33Neoplasm Metastasis 31Carcinoma, Transitional Cell 31Carcinoma, Renal Cell 29Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 15Prostatic Neoplasms 13Liver Neoplasms 13Glioblastoma 12Solid Tumors 11Recurrence 11Sarcoma 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Lymphoma 9Endometrial Neoplasms 9Mesothelioma, Malignant 8Kidney Neoplasms 8

Interventions

Trastuzumab 3pyrotinib 2pertuzumab 2tucatinib 1disitamab vedotin 1atezolizumab 1RC48 antibody 1Fulvestrant 1Docetaxel 1Capecitabine 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER2-positive Metastatic Breast Cancer × atezolizumab × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡